reports
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Simon Brun
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Simon Brun
- ABGSC Pulp & Paper Research
- Henrik Bartnes
- Martin Melbye
- ABGSC Pulp & Paper Research
- Henrik Bartnes
- Martin Melbye
Fabege AB: 1 director
A director at Fabege AB sold 81,927 shares at 82.520SEK and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Patrik Brattelius
- Simon Brun
Swedish Orphan Biovitrum AB: 3 directors
Three Directors at Swedish Orphan Biovitrum AB sold after exercising options/sold 208,150 shares at between 324.800SEK and 324.856SEK. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary ...
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to ...
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in patients with MAS in Still’s disease across MAS subtypes, including in those with recurrent disease Discussion of the first ever international, randomized, multicentre, double-blind, placebo-controlled phase 2 dose finding trial of Vonjo® (pacritinib) in adult patients with VEXAS syndrome WALTHAM, Mass., Oct. 25...
- ABGSC Pulp & Paper Research
- Henrik Bartnes
- Martin Melbye
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Simon Brun
- ABGSC Pulp & Paper Research
- Henrik Bartnes
- Martin Melbye
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Simon Brun
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Simon Brun
- ABGSC Pulp & Paper Research
- Henrik Bartnes
- Martin Melbye
- ABGSC Pulp & Paper Research
- Henrik Bartnes
- Martin Melbye
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
Hexagon AB: 1 director
A director at Hexagon AB sold 815,299 shares at 110.170SEK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.